CD7-targeted cell therapy for blood cancers
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new treatment using your own immune cells that are modified to find and attack cancer cells with a marker called CD7. It is for people with certain types of leukemia or lymphoma that have come back or not responded to standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 85 years old.
- You have a type of blood cancer (like T-cell leukemia/lymphoma or AML) that has returned or not improved after at least two prior treatments.
- Your cancer cells must have a specific marker called CD7 (found on at least 70% of the cancer cells).
- You must be able to donate your own blood cells for the treatment, or have a donor available.
- You should be in reasonably good health, with adequate organ function and an expected survival of more than 3 months.
- You must not have certain infections, severe heart conditions, or other major health issues that could make the treatment unsafe.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of immune cell therapy (CAR-T cells) that targets a specific marker called CD7 on blood cancer cells. It is for people whose blood cancer has not responded to other treatments or has come back after treatment.
This trial tests a new CAR T-cell therapy targeting CD7, a protein on some blood cancer cells. It is designed for patients whose T-cell leukemia/lymphoma or other CD7-positive blood cancer has not responded to standard treatments or has returned.
This trial tests a new treatment called CD7 CAR-T, which uses your own immune cells modified to find and attack cancer cells that have a protein called CD7 on their surface. It's for people with T-cell acute lymphoblastic leukemia or T-cell lymphoblastic lymphoma that has come back or not responded to standard treatments.
This trial studies a type of immune cell therapy (CAR-T) made from your own T-cells, designed to treat T-cell lymphoma or T-cell leukemia that has come back or didn’t respond. It may help by directing your immune system to attack the cancer, and it requires specific eligibility and safety checks.
This trial tests a new kind of immunotherapy called CD7 CAR-T therapy for people with T-cell cancers (like leukemia or lymphoma) that have come back or not responded to treatment. The CAR-T cells are made from your own immune cells or a donor's, and they are designed to find and destroy cancer cells that carry the CD7 marker.
This study tests a new type of immune cell therapy for people whose cancer cells have a specific marker called CD7. The treatment uses modified immune cells (CAR T-cells) to find and attack the cancer. It might help if other treatments haven't worked or the cancer has returned.
Hear when a new CD7-Positive Hematological Malignancies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.